diltiazem
| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.38 | $101.42 (0%) | 🛒 Add to cart |
| 60 | $2.71 | $202.84 $162.67 (20%) | 🛒 Add to cart |
| 90 | $2.50 | $304.26 $224.93 (26%) | 🛒 Add to cart |
| 120 | $2.38 | $405.67 $285.18 (30%) | 🛒 Add to cart |
| 180 | $2.26 | $608.51 $407.68 (33%) | 🛒 Add to cart |
| 270 | $2.19
Best per pill | $912.77 $592.44 (35%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.20 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $73.80 $70.29 (5%) | 🛒 Add to cart |
| 120 | $0.76 | $98.41 $91.38 (7%) | 🛒 Add to cart |
| 180 | $0.74 | $147.61 $132.55 (10%) | 🛒 Add to cart |
| 270 | $0.73 | $221.41 $195.81 (12%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $295.22 $258.06 (13%) | 🛒 Add to cart |
Diltiazem hydrochloride represents one of the most versatile cardiovascular agents in our modern pharmacopeia, a calcium channel blocker with a fascinatingly specific electrophysiological profile that makes it particularly useful for rate control in atrial fibrillation while also providing robust antianginal effects. When I first started using diltiazem in the late 1990s, we primarily thought of it as just another calcium channel blocker, but over two decades of clinical application have revealed its unique niche in cardiovascular therapeutics that sets it apart from both dihydropyridines like amlodipine and non-dihydrophyridines like verapamil.
Diltiazem: Comprehensive Cardiovascular Protection Through Calcium Channel Blockade - Evidence-Based Review
1. Introduction: What is Diltiazem? Its Role in Modern Medicine
Diltiazem belongs to the benzothiazepine class of calcium channel blockers, specifically categorized as a non-dihydropyridine calcium antagonist. What makes diltiazem particularly interesting clinically is its balanced effect on both vascular smooth muscle and cardiac conduction tissue - it produces coronary and peripheral vasodilation while simultaneously slowing atrioventricular nodal conduction. This dual mechanism explains why diltiazem finds application across multiple cardiovascular conditions including hypertension, chronic stable angina, vasospastic angina, and supraventricular tachyarrhythmias.
The drug was first synthesized in Japan in the 1970s and received FDA approval in the United States in the early 1980s. Since then, it has become a cornerstone therapy, especially for patients who require both blood pressure control and heart rate modulation. I remember when we first started using the extended-release formulations in the early 2000s - the improvement in adherence was immediately noticeable, though we did have some initial concerns about whether the pharmacokinetic profile would maintain the same therapeutic efficacy throughout the dosing interval.
2. Key Components and Bioavailability of Diltiazem
The chemical structure of diltiazem hydrochloride is (2S,3S)-3-acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochloride. The molecular formula is C22H26N2O4S·HCl with a molecular weight of 450.98. The drug exists as a white to off-white crystalline powder that’s freely soluble in water, methanol, and chloroform.
Bioavailability varies significantly between formulations. The immediate-release preparation demonstrates approximately 40% absolute bioavailability due to extensive first-pass metabolism, primarily via the CYP3A4 enzyme system in the liver and gut wall. The extended-release formulations (including Cardizem CD, Dilacor XR, Tiazac, and generic equivalents) are designed to provide more consistent plasma concentrations over 24 hours, though their absorption characteristics differ based on the specific delivery technology employed.
We learned this the hard way with one of my patients, Mr. Henderson - a 68-year-old with paroxysmal atrial fibrillation who was switched between different generic extended-release formulations due to insurance changes. His heart rate control became erratic until we realized the different formulations had meaningfully different peak-trough fluctuations despite similar labeled dosing intervals. This experience taught me to be particularly attentive to formulation consistency in patients with rhythm disorders.
Protein binding ranges from 70-80%, primarily to albumin and alpha-1-acid glycoprotein. The elimination half-life of immediate-release diltiazem is approximately 3-4.5 hours, while extended-release formulations extend this to 5-10 hours, though there’s considerable interindividual variation based on hepatic function and concomitant medications.
3. Mechanism of Action of Diltiazem: Scientific Substantiation
Diltiazem exerts its therapeutic effects through selective inhibition of calcium ion influx across cardiac and vascular smooth muscle cell membranes during depolarization, without significantly altering serum calcium concentrations. The drug binds to the alpha-1 subunit of L-type calcium channels, stabilizing them in their inactivated state and thereby reducing the number of available channels for activation during membrane depolarization.
What’s clinically crucial is the tissue selectivity - diltiazem has approximately equal affinity for vascular smooth muscle and cardiac conduction tissue, unlike dihydropyridines (which preferentially affect vasculature) or verapamil (which has stronger cardiac effects). This balanced profile explains why diltiazem produces moderate vasodilation while providing significant negative chronotropic and dromotropic effects on the sinoatrial and atrioventricular nodes.
The vascular effects result from decreased calcium availability for the contractile process in vascular smooth muscle, leading to coronary and peripheral arterial dilation. This reduces peripheral vascular resistance and afterload, which decreases myocardial oxygen demand - the primary antianginal mechanism. Simultaneously, coronary vasodilation increases myocardial oxygen supply.
The electrophysiological effects are particularly relevant for arrhythmia management. By prolonging conduction time and increasing refractoriness in the AV node, diltiazem effectively controls ventricular response in atrial fibrillation and flutter. The drug has minimal effect on the normal sinoatrial node function at therapeutic doses but can suppress abnormal automaticity in diseased nodes.
4. Indications for Use: What is Diltiazem Effective For?
Diltiazem for Hypertension
Diltiazem is approved for the management of hypertension, both as monotherapy and in combination with other antihypertensive agents. The blood pressure-lowering effect results from decreased peripheral vascular resistance without significant reflex tachycardia, which represents a distinct advantage over pure vasodilators. Multiple randomized controlled trials, including the ALLHAT and VALUE studies, have demonstrated that calcium channel blockers like diltiazem provide cardiovascular protection comparable to other first-line antihypertensive classes.
Diltiazem for Chronic Stable Angina
Through its dual mechanism of reducing myocardial oxygen demand (via decreased afterload and heart rate) and increasing oxygen supply (via coronary vasodilation), diltiazem effectively reduces angina frequency and improves exercise tolerance. The efficacy is comparable to beta-blockers, with the advantage of not causing bronchoconstriction - making it particularly valuable for patients with concomitant COPD or asthma.
Diltiazem for Vasospastic Angina
For Prinzmetal’s variant angina caused by coronary artery spasm, diltiazem is often particularly effective due to its direct coronary vasodilatory properties. The drug prevents spontaneous and ergonovine-induced coronary artery spasm, with studies showing complete abolition of attacks in approximately 70% of patients and marked reduction in frequency in most remaining cases.
Diltiazem for Atrial Fibrillation and Flutter
The negative dromotropic effect on the AV node makes diltiazem extremely valuable for rate control in atrial fibrillation and flutter. Intravenous diltiazem can achieve rate control within 2-3 minutes, while oral formulations provide maintenance therapy. The AFFIRM and RACE trials established the equivalence of rate versus rhythm control strategies, solidifying diltiazem’s role as a cornerstone therapy for AF management.
Diltiazem for Other Supraventricular Tachycardias
Beyond atrial fibrillation, diltiazem is effective for termination and prevention of reentrant tachycardias involving the AV node, including AV nodal reentrant tachycardia and orthodromic AV reentrant tachycardia using an accessory pathway.
5. Instructions for Use: Dosage and Course of Administration
Dosing must be individualized based on indication, formulation, and patient characteristics. The following table provides general guidance:
| Indication | Formulation | Initial Dose | Titration | Maintenance Range | Administration Instructions |
|---|---|---|---|---|---|
| Hypertension | Extended-release | 180-240 mg daily | 2-4 week intervals | 180-480 mg daily | Swallow whole, with or without food |
| Chronic Stable Angina | Immediate-release | 30 mg QID | 1-2 day intervals | 120-360 mg daily in divided doses | With meals to reduce GI upset |
| Atrial Fibrillation (rate control) | Extended-release | 120-180 mg BID | Weekly intervals | 120-360 mg BID | Consistent timing, avoid grapefruit |
| Vasospastic Angina | Extended-release | 120 mg daily | Weekly intervals | 120-480 mg daily | Evening dosing may prevent nocturnal attacks |
For elderly patients or those with hepatic impairment, initiation at the lower end of the dosing range is recommended. Renal impairment does not significantly affect diltiazem pharmacokinetics, though metabolites may accumulate in severe renal failure.
I learned about the importance of gradual titration with Mrs. Gable, a 72-year-old with hypertension who developed symptomatic bradycardia when we increased her dose from 180mg to 240mg too rapidly. We had to reduce the dose and implement much slower titration - over 6 weeks instead of 2 - to achieve the same blood pressure control without adverse effects.
6. Contraindications and Drug Interactions with Diltiazem
Diltiazem is contraindicated in patients with:
- Sick sinus syndrome (except with functioning ventricular pacemaker)
- Second- or third-degree AV block (except with functioning ventricular pacemaker)
- Hypotension (systolic <90 mmHg)
- Acute myocardial infarction with pulmonary congestion on x-ray
- Hypersensitivity to diltiazem
- Atrial fibrillation with Wolff-Parkinson-White syndrome
Significant drug interactions occur primarily through CYP3A4 inhibition and pharmacodynamic interactions:
| Interacting Drug Class | Examples | Mechanism | Clinical Effect | Management |
|---|---|---|---|---|
| Beta-blockers | Metoprolol, atenolol | Additive negative chronotropy/inotropy | Bradycardia, heart block, heart failure | Monitor HR, ECG; reduce doses |
| Statins | Simvastatin, lovastatin | CYP3A4 inhibition | Increased statin levels, myopathy risk | Use pravastatin, rosuvastatin; limit simvastatin to 10mg |
| Benzodiazepines | Midazolam, triazolam | CYP3A4 inhibition | Increased sedation | Reduce benzodiazepine dose |
| Cyclosporine | - | CYP3A4 inhibition | Nephrotoxicity | Monitor levels, reduce cyclosporine |
| Digoxin | - | Reduced renal clearance | Digoxin toxicity | Monitor levels, reduce digoxin |
Grapefruit juice significantly increases diltiazem bioavailability and should be avoided. The interaction can increase diltiazem concentrations by up to 3-fold, potentially leading to excessive bradycardia and hypotension.
7. Clinical Studies and Evidence Base for Diltiazem
The evidence supporting diltiazem spans decades and includes both landmark clinical trials and real-world observational studies:
The DAVIT II trial (1990) demonstrated that diltiazem administration following myocardial infarction reduced reinfarction and mortality in patients without pulmonary congestion. This established diltiazem’s safety in post-MI patients with preserved left ventricular function.
The INVEST trial (2003) compared verapamil-based and atenolol-based strategies in hypertensive patients with coronary artery disease, finding equivalent cardiovascular outcomes. While this study used verapamil, it reinforced the role of non-dihydropyridine calcium channel blockers in this population.
Multiple electrophysiology studies have quantified diltiazem’s effects on AV nodal conduction. Intravenous diltiazem increases the AV nodal refractory period by approximately 25% and prolongs the AH interval by 20-25%, with peak effects occurring within 2-3 minutes after bolus administration.
For hypertension, meta-analyses of randomized trials consistently show that diltiazem reduces systolic blood pressure by 8-12 mmHg and diastolic by 6-8 mmHg at standard doses, with response rates of 60-70% as monotherapy.
What surprised me in practice was discovering that some patients with “resistant” hypertension actually had pseudoresistance due to non-adherence - when we switched them to once-daily extended-release diltiazem from multiple daily dosing regimens, their blood pressure control improved dramatically without additional medications.
8. Comparing Diltiazem with Similar Products and Choosing a Quality Product
When selecting between calcium channel blockers, several considerations guide the choice:
| Parameter | Diltiazem | Verapamil | Amlodipine |
|---|---|---|---|
| Vasoselectivity | Balanced | Cardiac > Vascular | Vascular > Cardiac |
| Heart Rate Effect | Moderate decrease | Marked decrease | Minimal increase |
| AV Node Effect | Moderate prolongation | Marked prolongation | Minimal effect |
| Constipation Risk | Low | High | None |
| Preferred Indication | AF with hypertension | Hypertension with tachycardia | Isolated hypertension |
| Formulations | Multiple ER options | Limited ER options | Once daily |
Generic diltiazem is widely available and represents excellent value, though as mentioned earlier, formulation differences between manufacturers can affect clinical response in sensitive patients. For critical indications like rate control in atrial fibrillation, maintaining consistency with a specific manufacturer’s product is advisable.
The development of diltiazem extended-release formulations involved significant formulation challenges. Our hospital’s pharmacy committee actually had heated debates about whether to allow automatic therapeutic substitution between different extended-release products. The cardiologists (myself included) argued against it due to the clinical variability we’d observed, while the pharmacy department emphasized cost savings. We eventually compromised with a policy requiring physician approval for substitution in patients with arrhythmias or those stabilized on a specific product.
9. Frequently Asked Questions (FAQ) about Diltiazem
What monitoring is required during diltiazem therapy?
Baseline ECG and periodic heart rate and blood pressure checks are recommended. Liver function tests should be considered with long-term use, though significant hepatotoxicity is rare. For patients with heart failure, monitoring for worsening symptoms is important.
Can diltiazem be safely used in elderly patients?
Yes, though initial doses should be lower and titration more gradual due to reduced hepatic metabolism and increased sensitivity to bradycardia. The antihypertensive efficacy is preserved in older adults.
How quickly does intravenous diltiazem work for atrial fibrillation?
Heart rate reduction typically begins within 2-3 minutes after bolus administration, with peak effects at 5-7 minutes. The initial bolus of 0.25 mg/kg over 2 minutes can be followed by a second bolus of 0.35 mg/kg if response is inadequate.
What should I do if I miss a dose of diltiazem?
Take the missed dose as soon as remembered, unless it’s close to the next scheduled dose. Do not double the dose. For extended-release formulations, maintaining consistent timing is more important than with immediate-release.
Can diltiazem be used during pregnancy?
Diltiazem is FDA Pregnancy Category C, meaning risk cannot be ruled out. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Alternative agents with more pregnancy safety data are generally preferred.
10. Conclusion: Validity of Diltiazem Use in Clinical Practice
Diltiazem remains a cornerstone cardiovascular therapeutic with a well-established efficacy and safety profile across multiple indications. Its balanced effects on vascular tone and cardiac conduction provide unique advantages for patients with concomitant hypertension and supraventricular arrhythmias. The extensive clinical experience accumulated over four decades, supported by robust trial evidence, positions diltiazem as a versatile option in the cardiovascular armamentarium.
The development of extended-release formulations has enhanced the convenience and adherence profile, though attention to formulation-specific characteristics remains important, particularly for rhythm control. Ongoing research continues to explore novel applications, including potential benefits in microvascular angina and cardioprotection during cardiovascular procedures.
Looking back over my career, I’ve prescribed diltiazem to thousands of patients with generally excellent results. The case that stays with me is Mr. Davison, a 58-year-old lawyer with persistent atrial fibrillation and moderate hypertension who had failed multiple drug regimens due to side effects. We started him on extended-release diltiazem 240mg daily, and at his 3-month follow-up, not only was his heart rate controlled and blood pressure at goal, but he told me, “I finally feel like myself again - I can think clearly and have energy throughout the day.” Five years later, he remains on the same dose with maintained efficacy and no significant adverse effects. These longitudinal success stories, combined with the robust evidence base, continue to make diltiazem one of my most trusted cardiovascular agents.